MiMedx Group (NASDAQ:MDXG) Reaches New 52-Week Low – Here’s Why

MiMedx Group, Inc (NASDAQ:MDXG)’s stock price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $4.22 and last traded at $4.2230, with a volume of 295 shares. The stock had previously closed at $4.24.

Analyst Upgrades and Downgrades

MDXG has been the subject of several analyst reports. Mizuho dropped their price objective on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, December 17th. Citigroup started coverage on MiMedx Group in a report on Monday, February 23rd. They set a “market outperform” rating on the stock. Cantor Fitzgerald dropped their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. Citizens Jmp began coverage on shares of MiMedx Group in a research report on Monday, February 23rd. They set a “market outperform” rating and a $10.00 price objective for the company. Finally, Lake Street Capital reduced their price objective on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Stock Performance

The stock has a fifty day simple moving average of $5.03 and a two-hundred day simple moving average of $6.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.92 and a current ratio of 4.32. The stock has a market cap of $612.10 million, a price-to-earnings ratio of 12.88 and a beta of 1.60.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The company had revenue of $118.10 million during the quarter, compared to analysts’ expectations of $106.78 million. Analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in MDXG. First Light Asset Management LLC boosted its position in MiMedx Group by 89.5% in the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after buying an additional 1,725,458 shares in the last quarter. Divisadero Street Capital Management LP increased its holdings in shares of MiMedx Group by 362.9% during the second quarter. Divisadero Street Capital Management LP now owns 223,220 shares of the company’s stock worth $1,364,000 after buying an additional 175,000 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in shares of MiMedx Group during the third quarter worth $1,759,000. Trigran Investments Inc. lifted its stake in shares of MiMedx Group by 10.4% in the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock valued at $51,266,000 after acquiring an additional 790,901 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of MiMedx Group by 419.3% in the 3rd quarter. SG Americas Securities LLC now owns 161,960 shares of the company’s stock valued at $1,130,000 after acquiring an additional 130,769 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.